Eloxx Pharmaceuticals Appoints Chief Medical Officer

Rhea-AI Summary

Eloxx Pharmaceuticals has appointed Dr. Ali Hariri as Chief Medical Officer, focusing on clinical development of its pipeline targeting rare diseases. Previously at Sanofi, Dr. Hariri's experience in rare diseases will aid in advancing ELX-02, currently in Phase 2 trials for cystic fibrosis patients with nonsense mutations. The company expects data from the first four treatment arms of the Phase 2 study in Q4 2021, emphasizing the safety and biological activity of ELX-02.

Positive

• Appointment of a highly experienced Chief Medical Officer enhances leadership in clinical development.
• Dr. Hariri has a strong background in rare diseases, which is crucial for advancing the company’s pipeline.
• ELX-02 is in Phase 2 trials, with data expected soon, indicating progress in clinical development.

Negative

• None.

Ali Hariri, M.D. to Lead Clinical Development Efforts for Company Pipeline

WATERTOWN, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced the appointment of Ali Hariri, M.D., as its Chief Medical Officer, overseeing clinical development efforts for the company’s promising pipeline of therapies to treat rare diseases. Dr. Hariri will report to Vijay Modur, M.B.B.S., Ph.D., the company’s Head of Research and Development.

Dr. Hariri was previously Senior Global Project Head in Rare Disease Clinical Development at Sanofi where he oversaw key functions responsible for advancing a number of investigational therapies along with full approval for on-market therapies within the Sanofi Genzyme specialty care business. Prior to his role as Global Project Head at Sanofi Genzyme, Dr. Hariri held several positions of increasing responsibility with expertise across a range of therapeutic areas including nephrology and immunology. Before joining Sanofi, Dr. Hariri held clinical development roles at Ionis Pharmaceuticals and Takeda and was a practicing nephrologist.

“Our top priority at Eloxx remains the advancement of ELX-02, which is currently in Phase 2 clinical trials. Dr. Hariri’s experience in rare disease clinical development brings the type of skills necessary to advance this key imperative while quickly advancing our promising pre-clinical pipeline into human trials,” said Sumit Aggarwal, President and CEO of Eloxx.

The company reaffirmed its expectation that data from the first four treatment arms of the ELX-02 Phase 2 study will be available in the fourth quarter of 2021. ELX-02 is currently in Phase 2 clinical trials in CF patients affected by nonsense mutations in the CFTR (CF transmembrane conductance regulator) gene. The Phase 2 trials are designed to evaluate the safety of ELX-02 and assess its biological activity.

“The Eloxx pipeline has tremendous potential, and I’m thrilled to be joining a team with the skills and commitment to advance meaningful therapies on behalf of patients,” said Dr. Hariri.

Dr. Hariri earned his M.D. from the University of California San Diego School of Medicine, completed his residency at Case Western Reserve, and did his fellowship in nephrology at Yale University School of Medicine.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is engaged in the science of ribosome modulation, leveraging both its innovative TURBO-ZM™ chemistry technology platform in an effort to develop novel Ribosome Modulating Agents (RMAs) and its library of Eukaryotic Ribosome Selective Glycosides (ERSGs). Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in clinical development focusing on cystic fibrosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx also has preclinical programs focused on select rare diseases including inherited diseases, cancer caused by nonsense mutations, kidney diseases, including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders.

For more information, please visit www.eloxxpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts contained in this press release, including without limitation, statements regarding the expected timing of trials and results from clinical studies of our product candidate, the expansion of our clinical trial sites and the potential of our product candidate to treat nonsense mutations are forward-looking statements. Forward-looking statements can be identified by the words “aim,” “may,” “will,” “would,” “should,” “expect,” “explore,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “seeks,” or “continue” or the negative of these terms similar expressions, although not all forward-looking statements contain these words.

Forward-looking statements are based on management's current plans, estimates, assumptions and projections based on information currently available to us. Forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and actual results or outcomes may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: our ability to progress any product candidates in preclinical or clinical trials; the uncertainty of clinical trial results and the fact that positive results from preclinical studies are not always indicative of positive clinical results; the scope, rate and progress of our preclinical studies and clinical trials and other research and development activities; the competition for patient enrollment from drug candidates in development; the impact of the global COVID-19 pandemic on our clinical trials, operations, vendors, suppliers, and employees; our ability to obtain the capital necessary to fund our operations; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain financial in the future through product licensing, public or private equity or debt financing or otherwise; general business conditions, regulatory environment, competition and market for our products; and business ability and judgment of personnel, and the availability of qualified personnel and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, as any such factors may be updated from time to time in our other filings with the SEC, accessible on the SEC’s website at www.sec.gov and the “Financials & Filings” page of our website at https://investors.eloxxpharma.com/financial-information/sec-filings

All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact

Investors
John Woolford
john.woolford@westwicke.com
443.213.0506

Media
Laureen Cassidy
laureen@outcomescg.com

SOURCE: Eloxx Pharmaceuticals, Inc.

FAQ

Who is the new Chief Medical Officer of Eloxx Pharmaceuticals?

Dr. Ali Hariri has been appointed as the new Chief Medical Officer overseeing clinical development.

What is the focus of Dr. Hariri's role at Eloxx Pharmaceuticals?

Dr. Hariri will lead clinical development efforts for Eloxx's pipeline of therapies aimed at treating rare diseases.

What is the current status of the ELX-02 clinical trials?

ELX-02 is currently in Phase 2 clinical trials for cystic fibrosis patients with nonsense mutations, with data expected in Q4 2021.

What are the key qualifications of Dr. Hariri?

Dr. Hariri has extensive experience in rare disease clinical development, previously holding senior roles at Sanofi and others.